Novel multifunctional antibody approved for the treatment of breast cancer

OncoImmunology

Volumn 2, Issue 6, 2013, Pages

  Mavilio, Domenico ^a   Galluzzi, Lorenzo ^b,c,d   Lugli, Enrico ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Breast carcinoma; Cancer immunotherapy; Monoclonal antibodies; T DM1; Trastuzumab

Indexed keywords

EID: 84885351276     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24567     Document Type: Article

References (18)

1. Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautés-fridman C, Tartour E, et al. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2012; 1:28-37; PMID:22720209; http://dx.doi.org/10.4161/onci.1.1.17938.
2. Vacchelli E, Eggermont A, Galon J, Sautés-fridman C, Zitvogel L, Kroemer G, et al. Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013; 2:e22789; PMID:23482847; http://dx.doi.org/10.4161/onci.22789.
3. Scott AM, Wolchok JD, Old LJ. Antibody ther-apy of cancer. Nat Rev Cancer 2012; 12:278-87; PMID:22437872; http://dx.doi.org/10.1038/nrc3236.
4. Hubert P, Amigorena S. Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy. Oncoimmunology 2012; 1:103-5; PMID:22720225; http://dx.doi.org/10.4161/onci.1.1.17963.
5. Kute T, Stehle JR Jr., Ornelles D, Walker N, Delbono O, Vaughn JP. Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells. Oncoimmunology 2012; 1:810-21; PMID:23162748; http://dx.doi.org/10.4161/onci.20447.
6. Lindorfer MA, Wiestner A, Zent CS, Taylor RP. Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies? Oncoimmunology 2012; 1:959-61; PMID:23162771; http://dx.doi.org/10.4161/onci.20368.
7. Carter PJ, Senter PD. Antibody-drug conju-gates for cancer therapy. Cancer J 2008; 14:154-69; PMID:18536555; http://dx.doi.org/10.1097/PPO.0b013e318172d704.
8. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritu-momab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lympho-ma. J Clin Oncol 2002; 20:3262-9; PMID:12149300; http://dx.doi.org/10.1200/JCO.2002.11.017.
9. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352:441-9; PMID:15689582; http://dx.doi.org/10.1056/NEJMoa041511.
10. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363:1812-21; PMID:21047225; http://dx.doi.org/10.1056/NEJMoa1002965.
11. Adair JR, Howard PW, Hartley JA, Williams DG, Chester KA. Antibody-drug conjugates-a perfect synergy. Expert Opin Biol Ther 2012; 12:1191-206; PMID:22650648; http://dx.doi.org/10.1517/14712598.2012.693473.
12. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al.; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367:1783-91; PMID:23020162; http://dx.doi.org/10.1056/NEJMoa1209124.
13. Stern HM. Improving treatment of HER2-positive cancers: opportunities and challenges. Sci Transl Med 2012; 4(127): 127rv2; http://dx.doi.org/10.1126/sci-translmed.3001539; PMID: 22461643.
14. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012; 4:CD006243; PMID:22513938.
15. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626.
16. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 inter-actions for cancer immunotherapy. Oncoimmunology 2012; 1:1223-5; PMID:23243584; http://dx.doi.org/10.4161/onci.21335.
17. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-fridman C, et al. Trial Watch: Experimental Toll-like receptor agonists for can-cer therapy. Oncoimmunology 2012; 1:699-716; PMID:22934262; http://dx.doi.org/10.4161/onci.20696.
18. Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-fridman C, et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:894-907; PMID:23162757; http://dx.doi.org/10.4161/onci.20931.